July/August 2025 • PharmaTimes Magazine • 4-5

Contents

Features

GLP-1s – pharma’s $100bn+ opportunity to redefine obesity treatment

It’s here – but will it bring your innovations to market quicker?

Executing AI responsibly in drug safety could be a game changer

How biomarkers are shaping Parkinson’s diagnosis and trials

Getting real about artificial data in drug development

Analysis

Coming out of the dark – is it a new decade for the NHS?

Attempting to decode Parkinson’s disease with AI and the cloud

Supporting the veterinary workforce is vital to public health

How agentic AI is rewriting pharma’s commercial playbook

SmartPeople

13.
Future prescribed
Transforming community prescribing through innovation

19.
Talking the talk
Why supporting representative trial participation matters

24.
International superstars
The power and potential of study tokenisation for vaccine research and post-commercialisation

36.
New surroundings
Where you're going, and what you're doing when you arrive!

0
Logo

PharmaTimes

PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.

PharmaTimes print and digital magazine has a distributed circulation of 19,000, reaching right across the industry into every company and every function, bridging the gap between Pharma and the NHS.

editorial@pharmatimes.com
https://pharmatimes.com/
Privacy Policy
Terms of Service

Categories

Explore our inspiring content by topic

PharmaTimes
News
Features
Analysis
SmartPeople

Social Footprints

Follow us on our Social Media Channels

X
linkedin